Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer

BACKGROUND: PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We aimed to assess durvalumab plus tremelimuma...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Oncol
Main Authors: Antonia, Scott, Goldberg, Sarah B., Balmanoukian, Ani, Chaft, Jamie E., Sanborn, Rachel E., Gupta, Ashok, Narwal, Rajesh, Steele, Keith, Gu, Yu, Karakunnel, Joyson Joseph, Rizvi, Naiyer A.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5500167/
https://ncbi.nlm.nih.gov/pubmed/26858122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00544-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items